← Back to headlines
AbbVie Raises 2026 Outlook Driven by Skyrizi and Rinvoq
AbbVie has increased its 2026 outlook, with strong sales of Skyrizi and Rinvoq offsetting the decline in Humira sales.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Uber and Wayve Launch London’s First Autonomous Robotaxi Service
11m ago
Berkshire Hathaway Signals Intent to Increase Stakes in Japanese Trading Houses
33m ago
Rising US-Iran Military Tensions Spark Regional War Fears and Oil Volatility
38m ago
Diversified Energy to Acquire Elliott-Backed Birch Energy for $1.8 Billion
49m ago